Cargando…

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

BACKGROUND: Plaque psoriasis is a debilitating skin condition that affects approximately 2% of the adult population and for which there is currently no cure. Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. METHODS: The design of this study has been reported pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valenzuela, Fernando, Papp, Kim A, Pariser, David, Tyring, Stephen K, Wolk, Robert, Buonanno, Marjorie, Wang, Jeff, Tan, Huaming, Valdez, Hernan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436155/ https://www.ncbi.nlm.nih.gov/pubmed/25951857 http://dx.doi.org/10.1186/s12895-015-0025-y

Ejemplares similares

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
por: Strober, B.E., et al.
Publicado: (2018)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
por: Ports, WC, et al.
Publicado: (2013)

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
por: Di Lernia, V, et al.
Publicado: (2016)

CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors
por: Meng, Qingda, et al.
Publicado: (2018)

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019)

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
por: Xuying, Pei, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis
por: Tian, Fangyuan, et al.
Publicado: (2019)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial
por: Abe, Masatoshi, et al.
Publicado: (2017)

CMV and EBV Co-Infection in HIV-Infected Children: Infection Rates and Analysis of Differential Expression of Cytokines in HIV Mono- and HIV–CMV–EBV Co-Infected Groups
por: Nazim, Fizza, et al.
Publicado: (2022)

Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis
por: Tajalli, Mahroo, et al.
Publicado: (2020)

Congenital and Postnatal CMV and EBV Acquisition in HIV-Infected Zimbabwean Infants
por: Gumbo, Hlanai, et al.
Publicado: (2014)

IgM Positivity for Both EBV and CMV: A Clinical Conundrum
por: Jhaveri, Tulip A, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
por: Papp, Kim A., et al.
Publicado: (2021)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis
por: Wang, Xia, et al.
Publicado: (2010)

The prevalence of CMV and EBV among the patients with the colorectal cancer; a molecular approach
por: Arastefar, Amir, et al.
Publicado: (2015)

Overall avidity declines in TCR repertoires during latent CMV but not EBV infection
por: Couturaud, Barbara, et al.
Publicado: (2023)

Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Chronic Plaque Psoriasis
por: Mondal, Sudeshna, et al.
Publicado: (2022)

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
por: Papp, Kim A., et al.
Publicado: (2021)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa
por: Adjei, Andrew A, et al.
Publicado: (2008)

Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients
por: Rasmussen, NS, et al.
Publicado: (2015)

Hemophagocytic Lymphohistiocytosis in a Patient With Hodgkin lymphoma and Concurrent EBV, CMV, and Candida Infections
por: Mustafa Ali, Moaath, et al.
Publicado: (2017)

Age and CMV-Infection Jointly Affect the EBV-Specific CD8(+) T-Cell Repertoire
por: Lanfermeijer, Josien, et al.
Publicado: (2021)

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
por: Clowse, Megan E. B., et al.
Publicado: (2016)

BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study
por: Blazquez-Navarro, Arturo, et al.
Publicado: (2018)

Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System
por: van Stijn, Diana, et al.
Publicado: (2021)

Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment
por: Piscianz, Elisa, et al.
Publicado: (2014)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Immune recovery and the risk of CMV/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation
por: Janeczko, Małgorzata, et al.
Publicado: (2016)

Prevalence and molecular epidemiology of CMV and EBV among nurses working in pediatrics, transplantology, and primary health care
por: Zając, Patrycja W., et al.
Publicado: (2020)

Corrigendum: Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System
por: van Stijn, Diana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_in42fsmmldj853s5ff8g9or8ts